Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial
Authors
Öcal, O.Schütte, K.
Kupčinskas, J.
Morkunas, E.
Jurkeviciute, G.
de Toni, E. N.
Ben Khaled, N.
Berg, T.
Malfertheiner, P.
Klümpen, H. J.
Sengel, C.
Basu, B.
Valle, Juan W
Benckert, J.
Gasbarrini, A.
Palmer, D.
Seidensticker, R.
Wildgruber, M.
Sangro, B.
Pech, M.
Ricke, J.
Seidensticker, M.
Affiliation
Department of Radiology, University Hospital, Ludwig Maximilian University of Munich, Marchioninistrasse 15, 81377, Munich, GermanyIssue Date
2021
Metadata
Show full item recordAbstract
Purpose: To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib. Methods: A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response. Results: Forty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and 57.9 pg/mL most effectively predicted overall survival for IL-6 and IL-8, respectively. Patients with high IL-6 (HR, 4.1 [1.9-8.9], p < 0.001) and IL-8 (HR, 2.4 [1.2-4.7], p = 0.009) had significantly shorter overall survival than patients with low IL values. Multivariate analysis confirmed IL-6 (HR, 2.99 [1.22-7.3], p = 0.017) and IL-8 (HR, 2.19 [1.02-4.7], p = 0.044) as independent predictors of OS. Baseline IL-6 and IL-8 with respective cut-off values predicted objective response rates according to mRECIST in a subset of 42 patients with follow-up imaging available (IL-6, 46.6% vs. 19.2%, p = 0.007; IL-8, 50.0% vs. 17.4%, p = 0.011). Conclusion: IL-6 and IL-8 baseline values predicted outcomes of sorafenib-treated patients in this well-characterized prospective cohort of the SORAMIC trial. We suggest that the respective cut-off values might serve for validation in larger cohorts, potentially offering guidance for improved patient selection.Citation
Öcal O, Schütte K, Kupčinskas J, Morkunas E, Jurkeviciute G, de Toni EN, et al. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. J Cancer Res Clin Oncol. 2021 Apr 14Journal
Journal of Cancer Research and Clinical OncologyDOI
10.1007/s00432-021-03627-1PubMed ID
33855585Additional Links
https://dx.doi.org/10.1007/s00432-021-03627-1Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1007/s00432-021-03627-1
Scopus Count
Collections
Related articles
- miRNome Profiling Analysis Reveals Novel Hepatocellular Carcinoma Diagnostic, Prognostic and Treatment-Related Candidate Biomarkers: Post hoc Analysis of SORAMIC Trial.
- Authors: Morkunas E, Vaitkeviciute E, Inciuraite R, Kupcinskas J, Link A, Skieceviciene J, Alunni-Fabbroni M, Schütte K, Malfertheiner P, Varkalaite G, Ricke J
- Issue date: 2024
- High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.
- Authors: Shao YY, Lin H, Li YS, Lee YH, Chen HM, Cheng AL, Hsu CH
- Issue date: 2017 Oct 1
- Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
- Authors: Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M, SORAMIC study group
- Issue date: 2022 Jan 4
- Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
- Authors: Lyu N, Kong Y, Mu L, Lin Y, Li J, Liu Y, Zhang Z, Zheng L, Deng H, Li S, Xie Q, Guo R, Shi M, Xu L, Cai X, Wu P, Zhao M
- Issue date: 2018 Jul
- Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma.
- Authors: Iida-Ueno A, Enomoto M, Uchida-Kobayashi S, Hagihara A, Teranishi Y, Fujii H, Morikawa H, Murakami Y, Tamori A, Thuy LTT, Kawada N
- Issue date: 2018 Nov